Lumanity Value, Access & Outcomes

Did you miss our April webinar exploring the Inflation Reduction Act (IRA) and EU Joint Clinical Assessment (JCA)? The IRA and EU JCA are two of the most seismic changes to the value and access landscape in a generation and require careful planning and consideration by manufacturers to navigate them successfully. Watch the recording of our webinar here and contact us if we can be of any assistance: https://buff.ly/3xThyb7. #LumanityPerspectives #InflationReductionAct #IRA #EUHTARegulation #EUHTA #JCA #HEOR

Why should stakeholder engagement sit at the heart of your value communication strategy? In our view, we explore how engaging your internal stakeholders will help you to develop coherent and concise evidence-based messaging that ensures alignment among your affiliates. Click here to read our view: https://buff.ly/3xXAvcH #LumanityPerspectives #HEOR #HTA #ValueCommunications #StakeholderEngagement

The EU Health Technology Assessment (HTA) Regulation represents the biggest shake-up of HTA possibly in history, as the 27 member states of the European Union adopt joint clinical assessment (JCA) of health technologies beginning in 2025. Lumanity has been at the forefront of developments on the new Regulation since it came into force in January 2022. Use the link below to navigate to our website where we have collated all of our articles on this topic, as well as details of our training program and key contacts to get in touch with for assistance. https://buff.ly/4cSOjnA #HEOR #HTA #EUHTARegulation #EUHTA

Thinking about your next career move? Check out current openings at Lumanity! Whether you’re an experienced professional or a recent graduate, join Lumanity to make a difference. We are a collaborative, global team—no matter where you live, you can help us build a healthier world. View all available positions at: https://buff.ly/3S2HvMk #healthcarecareers #healtheconomics #outcomesresearch #marketaccess #HEOR

Our Value, Access & Outcomes experts can help you unlock the full potential of your products and demonstrate their value to stakeholders around the world. Visit our website and find out why our clients choose Lumanity as their pharmaceutical Market Access and HEOR partner. https://lumanity.com/ #HealthEconomics #OutcomesResearch #HEOR #MarketAccess

Defining a “clinically distinct” target population and addressing the limitations of trial evidence are just two of the challenges manufacturers face when trying to demonstrate the value of drugs for treating rare diseases. In our whitepaper the team explores seven key challenges in this area and offers approaches to help: https://buff.ly/3zFlD3i #LumanityPerspectives #HTA #HEOR #RareDiseases

If you want to find out what the new EU HTA Regulation will mean for you, our experts can help you to prepare for the regulation’s impacts, including by delivering bespoke training for individuals and teams. Visit our dedicated EU HTA regulation webpage to find out more and explore how we can help you to navigate the complex and evolving European HTA landscape. https://buff.ly/3VYMX3V #Training #HealthEconomics #HEOR

Read our article on EU HTA regulation! The article includes an interactive map to summarize the self-reported key challenges, opportunities and readiness scores for each Member State as we get closer to the EU HTA Regulation’s first implementation phase. It also explores what delays in the majority of the implementation acts for the EU HTA Regulation will mean for industry participants trying to prepare for the Regulation’s impact. Read the article below and contact us to find out how we can help you to prepare. https://buff.ly/4bzsatD #LumanityPerspectives #EUHTA Regulation #HEOR #HTA

Lumanity is the pharmaceutical market access and HEOR partner that can help you to uncover the full potential of your products and demonstrate their value to stakeholders around the world. Visit our website and discover our Value, Access & Outcomes solutions: https://buff.ly/3Lgk52h #HealthEconomics #OutcomesResearch #HEOR #MarketAccess

Hilda de Jong PhD (PHARMO Institute for Drug Outcomes Research) has authored a new piece, "Target Trial Emulation Framework as a Tool of Causal Inference", which summarizes key takeaways from the course ‘Learn to use Target Trial Emulation for Regulatory Real-World Evidence Generation’, held in March 2024 and facilitated by PHARMO’s collaborators in The SIGMA Consortium. In the piece, Hilda explores the advantages of target trial emulation (TTE), including how TTE-oriented study designs can improve real world evidence (RWE) acceptability, mitigate bias, evaluate clinically relevant treatment strategy, and overcome temporal challenges. Read the article now: https://buff.ly/3RX88Ch #RealWorldEvidence #TargetTrialEmulation #PHARMOInstitute #Lumanity #SIGMAConsortium #ResearchInnovation #RWE #RWD #Pharmacovigilance #DrugSafety #PostAuthorisationSafetyStudy #PASS